Our equity story

UCB’s Decade+ of Growth: Elevating lives of people through our medicines

 

 

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

 

Growth drivers

 

BIMZELX® (bimekizumab)

Reaching more than >116 000 patients globally in 2025

Indications: Psoriasis (PSO); Psoriatic Arthritis (PsA); Ankylosing spondylitis (AS); non-radiographic Axial Spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS)

Loss of Exclusivity (indicative): 2035 in U.S., without patent term extension; 2036 in Europe, 2037 in Japan

Sales: € 2.2bn million in FY 2025

Peak sales guidance: > € 4 billion

 

EVENITY® (romosozumab)

Reached more than 1 300 000 patients globally since launch

Indication: Osteoporosis

Loss of Exclusivity (indicative): 2031 in Europe and Japan, 2033 in U.S.

Sales: € 137 million in FY 2025 in Europe. Net sales outside Europe reported by Amgen and Astellas

 

FINTEPLA® (fenfluramine)

Reaching more than 14 000 patients globally

Indications: Dravet Syndrome, Lennox-Gastaut Syndrome.

Loss of Exclusivity (indicative). 2032 in Europe and Japan, 2033 in U.S.

Sales: € 427 million in FY 2025.

Peak sales guidance: € 800 million by 2027.

 

RYSTIGGO® (rozanolixizumab)

Launched in the U.S. in July 2023, approved and launched in Europe and Japan

Indication: generalized Myasthenia Gravis.

Loss of Exclusivity (indicative): 2037 in Japan. 2034 in Europe and 2035 in U.S., all without patent term extension.

Sales: € 332 million in FY 2025.

 

ZILBRYSQ® (zilucoplan)

Global launches started April 2024

Indication: generalized Myasthenia Gravis.

Loss of Exclusivity (indicative): 2035 in Europe, U.S. without patent term extension. Japan 2040.

 

Solid foundation

 

BRIVIACT® (brivaracetam)

Indication: Epilepsy partial-onset seizure, also known as focal seizure

Loss of Exclusivity (indicative): 2026 in Europe & U.S. and 2034 in Japan

Sales: €758 million in FY 2025

Peak sales guidance: ≥ € 600 million by 2026, reached 2 years ahead of time

 

CIMZIA® (certolizumab pegol)

Indications: Ankylosing spondylitis (AS); non-radiographic Axial Spondyloarthritis (nr-axSpA); Crohn's disease (CD); Psoriasis (PSO); Psoriatic arthritis (PsA); Rheumatoid arthritis (RA)

Loss of Exclusivity (indicative): 2026 in Japan.

Sales: € 1 954 million in FY 2025

 

KEPPRA® (levetiracetam)

Indications: Epilepsy partial-onset seizures, also known as focal seizures; Epilepsy primary generalized tonic-clonic seizures; Epilepsy myoclonic seizures

Sales: € 439 million in FY 2025

 

NAYZILAM® (midazolam nasal spray)

Indication: Epilepsy seizure clusters

Loss of Exclusivity (indicative): 2028 in U.S.

Sales: € 128 million in FY 2025

 

VIMPAT® (lacosamide)

Indications: Epilepsy partial-onset seizures, also known as focal seizures; Epilepsy primary generalized tonic-clonic seizures

Loss of Exclusivity: 2022 in Europe & U.S. 2024 in Japan

Sales: € 303 million in FY 2025

 

Our clinical development partnerships

Amgen
Biogen
Cancer Research UK

 

Our clinical development pipeline

UCB remains committed to innovation, continuously seeking new ways to deliver meaningful solutions for people living with severe immunological and neurological conditions. This commitment is reflected in its robust clinical development pipeline, which currently includes one post-approval (Phase 4) asset, one asset in submission, and a diversified portfolio of four Phase 3 and three Phase 2 programs targeting distinct patient populations. Also in 2025, UCB has initiated three global Phase 3 studies for bimekizumab in pediatric indications: psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. In addition, the company plans to launch in 2026 a phase 3 program with fenfluramine for patients with Rett-syndrome and a phase 3 program with rosanolixizumab in ocular myasthenia gravis (oMG). UCB will explore the potential of galvokimig in respiratory diseases: two respiratory indications, Chronic Obstructive Pulmonary Disease (COPD) and non-cystic fibrosis bronchiectasis (NCFB), with respective proof of concept studies (phase 2a) are starting later in 2026.

  • bimekizumab (IL-17 A/F)

    Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Post-approval head-to-head study versus risankizumab in PsA

    PHASE: 4

    INFO: First headline results H1 2026

  • bimekizumab (IL-17 A/F)

    Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Palmoplantar Pustulosis (PPP)

    PHASE: 3

    INFO: First headline results 2028

  • rozanolixizumab (FcRn inhibitor)

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Neurology

    INDICATION: Myelin oligodendrocyte glycoprotein (MOG) antibody disease

    PHASE: 3

    INFO: Headline results H2 2026

  • rozanolixizumab (FcRn inhibitor)

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Neurology

    INDICATION: Ocular myasthenia gravis

    PHASE: 3

    INFO: Phase 3 to start in 2026

  • fenfluramine (5-HT agonist)

    Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: CDKL5 deficiency disorder

    PHASE: 3

    INFO: Positive Phase 3 - Regulatory submission under preparation

  • fenfluramine (5-HT agonist)

    Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: RETT-Syndrome

    PHASE: 3

    INFO: Phase 3 to start in H1 2026

  • dapirolizumab pegol (anti-CD40L antibody)

    Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.

    Dapirolizumab pegol is being co-developed with Biogen. 1st phase 3 study.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Systemic lupus erythematosus

    PHASE: 3

    INFO: 1st positive Phase 3 - 2nd Phase 3: 2028

  • STACCATO® alprazolam (benzodiazepine)

    STACCATO® alprazolam is an investigational drug-device combination using STACCATO® delivery technology with alprazolam, a benzodiazepine, that has the potential to be the first rescue treatment to be administered by a patient or caregiver in an out-patient setting to rapidly terminate (within 90 seconds) an ongoing seizure.

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: Stereotypical prolonged seizures

    PHASE: 3

    INFO: Headline results H2 2026

  • bepranemab (anti-tau antibody)

    Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Neurology

    INDICATION: Alzheimer's disease

    PHASE: 2

    INFO: Encouraging Phase 2a - Fast Track designation

  • glovadalen / UCB0022 (D1 receptor positive allosteric modulators)

    Glovadalen is an investigational selective dopamine D1 receptor positive allosteric modulator. This orally available, brain-penetrant, small molecule is designed to enhance the potency of dopamine ‘when and where needed’ to activate the dopamine D1 receptor and thereby improve symptom control. It is being studied for the treatment of Parkinson's disease.

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: Parkinson's disease

    PHASE: 2

    INFO: Positive Phase 2a. Next steps under evaluation

  • galvokimig / UCB9741 (IL-17 A/F & IL-13)

    Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with an extended half-life through albumin binding. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Atopic dermatitis

    PHASE: 2

    INFO:Phase 2b started, first results in 2028

  • galvokimig / UCB9741 (IL-17 A/F & IL-13)

    Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with an extended half-life through albumin binding. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Non Cystic Fibrosis Bronchiectasis (NCFB)

    PHASE: 2

    INFO:Phase 2a to start in 2026

  • galvokimig / UCB9741 (IL-17 A/F & IL-13)

    Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with an extended half-life through albumin binding. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Chronic Obstructive Pulmonary Disease (COPD)

    PHASE: 2

    INFO:Phase 2a to start in 2026